NCT02279004View on ClinicalTrials.gov

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

RecruitingOBSERVATIONAL

Enrollment

840

Participants

Timeline

Start Date

July 3, 2014

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

NSCLCMelanoma

Trial Locations (1)

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Damon Runyon Cancer Research Foundation

OTHER

lead

Dana-Farber Cancer Institute

OTHER